Shots:

• Presage utilizes its CIVO intratumoral microdosing platform to evaluate Celgene's early stage products in P-0 trial
• The collaboration follows safety & feasibility of CIVO in sarcoma patients- a clinical trial conducted by Presage which demonstrated well-tolerated data and the results are expected to be published in H2’19
• Presage's CIVO platform is an intratumoral microdosing platform used to evaluate patients' unique responses to microdoses of multiple cancer drugs and is helpful in the drug development process

Ref: PRNewsWire | Image: Wall Street Journal